737 related articles for article (PubMed ID: 22532316)
21. Cytomegalovirus Infection After Intestinal/Multivisceral Transplantation: A Single-Center Experience With 210 Cases.
Nagai S; Mangus RS; Anderson E; Ekser B; Kubal CA; Fridell JA; Tector AJ
Transplantation; 2016 Feb; 100(2):451-60. PubMed ID: 26247555
[TBL] [Abstract][Full Text] [Related]
22. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.
Shiley KT; Gasink LB; Barton TD; Pfeiffenberger P; Olthoff KM; Blumberg EA
Liver Transpl; 2009 Aug; 15(8):963-7. PubMed ID: 19642123
[TBL] [Abstract][Full Text] [Related]
23. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients.
Lisboa LF; Preiksaitis JK; Humar A; Kumar D
Transplantation; 2011 Nov; 92(9):1063-8. PubMed ID: 21878838
[TBL] [Abstract][Full Text] [Related]
24. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
Witzke O; Nitschke M; Bartels M; Wolters H; Wolf G; Reinke P; Hauser IA; Alshuth U; Kliem V
Transplantation; 2018 May; 102(5):876-882. PubMed ID: 29166336
[TBL] [Abstract][Full Text] [Related]
25. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC
Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523
[TBL] [Abstract][Full Text] [Related]
26. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
[TBL] [Abstract][Full Text] [Related]
27. The role of secondary cytomegalovirus prophylaxis for kidney and liver transplant recipients.
Sullivan T; Brodginski A; Patel G; Huprikar S
Transplantation; 2015 Apr; 99(4):855-9. PubMed ID: 25208322
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation.
Lapidus-Krol E; Shapiro R; Amir J; Davidovits M; Steinberg R; Mor E; Avitzur Y
Pediatr Transplant; 2010 Sep; 14(6):753-60. PubMed ID: 20477976
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients.
Liu AW; Jutivorakool K; Fisher CE; Rakita RM; Reyes JD; Bhattacharya RB; Jerome KR; Limaye AP
Transplantation; 2018 Apr; 102(4):632-639. PubMed ID: 29215460
[TBL] [Abstract][Full Text] [Related]
30. Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort.
Meije Y; Fortún J; Len Ó; Aguado JM; Moreno A; Cisneros JM; Gurguí M; Carratalà J; Muñoz P; Montejo M; Blanes M; Bou G; Pérez JL; Torre-Cisneros J; Ramos A; Pahissa A; Gavaldà J;
Transpl Infect Dis; 2014 Jun; 16(3):387-96. PubMed ID: 24807640
[TBL] [Abstract][Full Text] [Related]
31. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
[TBL] [Abstract][Full Text] [Related]
32. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
Fernández-Ruiz M; Arias M; Campistol JM; Navarro D; Gómez-Huertas E; Gómez-Márquez G; Díaz JM; Hernández D; Bernal-Blanco G; Cofan F; Jimeno L; Franco-Esteve A; González E; Moreso FJ; Gómez-Alamillo C; Mendiluce A; Luna-Huerta E; Aguado JM;
Transpl Int; 2015 Sep; 28(9):1042-54. PubMed ID: 25864986
[TBL] [Abstract][Full Text] [Related]
33. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
[TBL] [Abstract][Full Text] [Related]
34. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
[TBL] [Abstract][Full Text] [Related]
35. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
Cervera C; Pineda M; Linares L; Marcos MA; Esteva C; Antón A; Cofán F; Ricart MJ; Navasa M; Pérez-Villa F; Pumarola T; Moreno A
Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146
[TBL] [Abstract][Full Text] [Related]
36. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
[TBL] [Abstract][Full Text] [Related]
37. The value of pre-emptive therapy for cytomegalovirus after liver transplantation.
Müller V; Perrakis A; Meyer J; Förtsch T; Korn K; Croner RS; Yedibela S; Hohenberger W; Schellerer VS
Transplant Proc; 2012 Jun; 44(5):1357-61. PubMed ID: 22664015
[TBL] [Abstract][Full Text] [Related]
38. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients.
Potena L; Grigioni F; Magnani G; Lazzarotto T; Musuraca AC; Ortolani P; Coccolo F; Fallani F; Russo A; Branzi A
J Heart Lung Transplant; 2009 May; 28(5):461-7. PubMed ID: 19416774
[TBL] [Abstract][Full Text] [Related]
39. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.
Singh N; Wannstedt C; Keyes L; Gayowski T; Wagener MM; Cacciarelli TV
Transplantation; 2005 Jan; 79(1):85-90. PubMed ID: 15714174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]